Zyla Life Sciences Deferred Tax Assets, Gross
Zyla Life Sciences had Deferred Tax Assets, Gross of $97.05 million as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2020-03-26
- 2019-12-31: Deferred Tax Assets, Gross $97.05M.
- 2018-12-31: Deferred Tax Assets, Gross $80.37M.
- 2017-12-31: Deferred Tax Assets, Gross $63.14M.
- 2016-12-31: Deferred Tax Assets, Gross $59.32M.
| Period end | Deferred Tax Assets, Gross | Deferred Tax Assets, Gross as first filed |
|---|---|---|
| 2019-12-31 | $97.05M 10-K · filed 2020-03-26 | |
| 2018-12-31 | $80.37M 10-K · filed 2020-03-26 | |
| 2017-12-31 | $63.14M 10-K · filed 2019-03-29 | |
| 2016-12-31 | $59.32M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $31.08M 10-K · filed 2017-03-13 | |
| 2014-12-31 | $14.05M 10-K · filed 2016-03-11 | $14.05M 10-K · filed 2015-03-16 |
| 2013-12-31 | $5.30M 10-K · filed 2015-03-16 |